MA44875A - Compositions pour le traitement de troubles acido-basiques - Google Patents

Compositions pour le traitement de troubles acido-basiques

Info

Publication number
MA44875A
MA44875A MA044875A MA44875A MA44875A MA 44875 A MA44875 A MA 44875A MA 044875 A MA044875 A MA 044875A MA 44875 A MA44875 A MA 44875A MA 44875 A MA44875 A MA 44875A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
acid basic
disorders
basic disorders
Prior art date
Application number
MA044875A
Other languages
English (en)
French (fr)
Inventor
Kalpesh N Biyani
Jerry M Buysse
Eric F Connor
Michael J Cope
Randi K Gbur
Matthew J Kade
Paul H Kierstead
Gerrit Klaerner
Son H Nguyen
Scott M Tabakman
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of MA44875A publication Critical patent/MA44875A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
MA044875A 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques MA44875A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662333059P 2016-05-06 2016-05-06
US201662350686P 2016-06-15 2016-06-15
US201662408885P 2016-10-17 2016-10-17
US201662414966P 2016-10-31 2016-10-31

Publications (1)

Publication Number Publication Date
MA44875A true MA44875A (fr) 2019-03-13

Family

ID=59315687

Family Applications (3)

Application Number Title Priority Date Filing Date
MA044875A MA44875A (fr) 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques
MA054925A MA54925A (fr) 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques
MA044886A MA44886A (fr) 2016-05-06 2017-05-05 Compositions et méthode pour traiter des troubles acide-base

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA054925A MA54925A (fr) 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques
MA044886A MA44886A (fr) 2016-05-06 2017-05-05 Compositions et méthode pour traiter des troubles acide-base

Country Status (15)

Country Link
US (6) US11406661B2 (enExample)
EP (3) EP3831395A1 (enExample)
JP (3) JP7071284B2 (enExample)
KR (1) KR102655774B1 (enExample)
CN (2) CN109414453B (enExample)
AU (3) AU2017261337A1 (enExample)
BR (1) BR112018072714A2 (enExample)
CA (1) CA3023264A1 (enExample)
IL (2) IL308673A (enExample)
MA (3) MA44875A (enExample)
MX (1) MX2018013476A (enExample)
MY (1) MY197091A (enExample)
RU (1) RU2018142943A (enExample)
SG (1) SG11201809605PA (enExample)
WO (3) WO2017193050A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733493T3 (es) 2013-06-05 2019-11-29 Tricida Inc Polímeros de unión a protones para la administración oral
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CA3079171C (en) * 2017-10-16 2023-09-12 Fujifilm Corporation Therapeutic agent for hyperphosphatemia and particles
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
SG11202003453QA (en) * 2017-11-03 2020-05-28 Tricida Inc Method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236636A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
EP4053179B1 (en) 2021-03-01 2025-08-27 Renosis, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
KR20230163415A (ko) 2021-03-01 2023-11-30 트리시다, 인크. 가교된 폴리(알릴아민) 중합체 제약 조성물
WO2023109825A1 (zh) * 2021-12-14 2023-06-22 上海石趣医药科技有限公司 氧化银和/或其水合物在制备药物中的用途
WO2023109826A1 (zh) * 2021-12-14 2023-06-22 上海石趣医药科技有限公司 碳酸银在制备药物中的用途

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
AU703842B2 (en) 1994-10-17 1999-04-01 Robert M. Bersin Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
WO1999040990A1 (en) 1998-02-17 1999-08-19 University Of Maryland Anion binding polymers and the use thereof
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
WO2001066607A1 (en) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
US20040059065A1 (en) 2000-03-09 2004-03-25 Takeshi Goto Crosslinked anion-exchange resin or salt thereof
AU2001241095A1 (en) 2000-03-13 2001-09-24 Hisamitsu Pharmaceutical Co. Inc. Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
AT409630B (de) * 2000-12-13 2002-09-25 Dsm Fine Chem Austria Gmbh Alkylierung von n-bzw. amino- oder ammoniumgruppen haltigen, vernetzten polymeren
BR0209133A (pt) 2001-04-18 2004-06-15 Genzyme Corp Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
BR0209020A (pt) 2001-04-18 2004-08-10 Genzyme Corp Composição farmacêutica de polialilamina
EP1483232A1 (en) 2002-03-11 2004-12-08 Novartis AG Salts of nateglinide
AU2004210013A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
JP2007517047A (ja) 2003-12-31 2007-06-28 ジェンザイム・コーポレーション 腸溶コーティングされた脂肪族アミンポリマーの胆汁酸捕捉因子
WO2005072773A1 (ja) 2004-01-29 2005-08-11 Keio University 赤血球機能修飾物質
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
GB2430368B (en) 2004-03-30 2009-08-26 Ilypsa Inc Methods and compositions for treatment of ion imbalances
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
RU2633071C2 (ru) 2004-07-19 2017-10-11 Н.В. Нютрисиа Препарат для применения аспартата и витамина в12 или биотина для регуляции кетоновых тел
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
JP5667343B2 (ja) 2005-08-18 2015-02-12 パニオン アンド ビーエフ バイオテック インコーポレーテッド 医薬グレードの第二鉄有機化合物、その使用およびその製造方法
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
CN101321519A (zh) 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN101316601A (zh) 2005-09-30 2008-12-03 伊立普萨公司 从哺乳动物的胃肠道选择性除去钾离子的方法和组合物
CN101355953B (zh) 2005-11-08 2014-07-09 味之素株式会社 麻醉苏醒促进剂
WO2007056405A2 (en) 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
JP2009536246A (ja) 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
EP2043627A2 (en) 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
CA2658338A1 (en) 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2046284A1 (en) 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
BRPI0717008A2 (pt) 2006-09-01 2014-01-21 Usv Ltd Processo para o preparo de cloridrato de sevelamer e formulação do mesmo
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
WO2008027551A2 (en) 2006-09-01 2008-03-06 Genzyme Corporation Dendrimer compositions
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
WO2008042222A2 (en) 2006-09-29 2008-04-10 Genzyme Corporation Amide dendrimer compositions
WO2008076242A1 (en) 2006-12-14 2008-06-26 Genzyme Corporation Amido-amine polymer compositions
EP2114376A1 (en) 2007-02-23 2009-11-11 Genzyme Corporation Amine polymer compositions
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
WO2008109095A1 (en) 2007-03-08 2008-09-12 Genzyme Corporation Sulfone polymer compositions
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
US20100166696A1 (en) 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
US8273384B2 (en) 2007-07-02 2012-09-25 Stephen Ray Wurzberger Process for the preparation of a non-corrosive base solution and methods of using same
WO2009008480A1 (ja) 2007-07-11 2009-01-15 Toray Industries, Inc. 架橋ポリアリルアミン又はその酸付加塩、及びその医薬用途
EP2016947A1 (en) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
WO2009023544A2 (en) 2007-08-10 2009-02-19 Ilypsa, Inc. Dosage unit anion-exchange polymer pharmaceutical compositions
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
JP2011506449A (ja) 2007-12-14 2011-03-03 ジェンザイム コーポレーション コーティング医薬組成物
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
WO2009097127A1 (en) 2008-01-31 2009-08-06 Genzyme Corporation Pharmaceutical compositions
WO2009114650A1 (en) 2008-03-11 2009-09-17 Chakshu Research, Inc. Methods and compositions for treating inflammation and inflammation-related pathologies
CA2720865A1 (en) 2008-04-08 2009-10-15 Usv Limited Process for preparation of amine polymer salt
WO2009154747A1 (en) 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
EP2348834B1 (en) 2008-09-25 2018-04-18 Vive Crop Protection Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010059384A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
AU2010209293A1 (en) * 2009-01-22 2011-09-08 Usv Limited Pharmaceutical compositions comprising phosphate-binding polymer
EP2488172A4 (en) 2009-10-13 2014-08-13 Univ Michigan DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS
DK2490675T3 (en) 2009-10-22 2019-04-29 Synthon Bv Pharmaceutical compositions with sevelamer
CN102822194B (zh) 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
ES2598500T3 (es) 2010-02-24 2017-01-27 Relypsa, Inc. Poliimidazoles para su uso como secuestrantes de ácidos biliares
US9181364B2 (en) 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
EA201590062A1 (ru) 2012-06-21 2016-02-29 Керикс Байофармасьютикалз, Инк. Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью
AU2013329451B2 (en) 2012-10-08 2018-08-09 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia
ES2733493T3 (es) 2013-06-05 2019-11-29 Tricida Inc Polímeros de unión a protones para la administración oral
SG11201603091QA (en) 2013-11-04 2016-05-30 Keryx Biopharmaceuticals Inc Ferric citrate for reducing cardiac failure in chronic kidney disease patients
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
SG11202003453QA (en) 2017-11-03 2020-05-28 Tricida Inc Method of treating acid-base disorders
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236636A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236124A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
MY197091A (en) 2023-05-24
AU2017261337A1 (en) 2018-11-15
JP2022106914A (ja) 2022-07-20
EP3452028A1 (en) 2019-03-13
WO2017193024A1 (en) 2017-11-09
JP2025157428A (ja) 2025-10-15
IL308673A (en) 2024-01-01
CN109414453A (zh) 2019-03-01
CN109414453B (zh) 2023-02-17
AU2023202111B2 (en) 2025-05-15
EP3452057A1 (en) 2019-03-13
US20210205351A1 (en) 2021-07-08
WO2017193024A9 (en) 2018-11-22
KR102655774B1 (ko) 2024-04-05
AU2023202111A1 (en) 2023-05-04
WO2017193050A1 (en) 2017-11-09
JP7071284B2 (ja) 2022-05-18
IL262660A (en) 2018-12-31
IL262660B1 (en) 2023-12-01
US20190134076A1 (en) 2019-05-09
MX2018013476A (es) 2019-03-28
SG11201809605PA (en) 2018-11-29
MA44886A (fr) 2019-03-13
AU2025217383A1 (en) 2025-09-04
US20190209607A1 (en) 2019-07-11
US11406661B2 (en) 2022-08-09
US20200054669A1 (en) 2020-02-20
RU2018142943A3 (enExample) 2020-08-10
US11992501B2 (en) 2024-05-28
RU2018142943A (ru) 2020-06-08
EP3452028A4 (en) 2020-04-15
KR20180133931A (ko) 2018-12-17
EP3831395A1 (en) 2021-06-09
BR112018072714A2 (pt) 2019-02-19
CA3023264A1 (en) 2017-11-09
CN116211887A (zh) 2023-06-06
IL262660B2 (en) 2024-04-01
MA54925A (fr) 2021-12-22
US20220062328A1 (en) 2022-03-03
JP2019514965A (ja) 2019-06-06
WO2017193064A1 (en) 2017-11-09
US20250009785A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
FR25C1001I1 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3448875A4 (en) Compositions for the treatment of disease
EP3340982A4 (en) COMPOUNDS FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISEASES
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448398A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
EP3328376A4 (en) Methods and compositions for treating metabolic reprogramming disorders
EP3465212A4 (en) REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP3704108A4 (en) COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF HEMATOLOGICAL DISORDERS
EP3500267A4 (en) NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3352749A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3328864A4 (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND DRUG ABUSE
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3344325A4 (en) LOCAL ADMINISTRATION OF MEDICAMENTS FOR THE TREATMENT OF ASTHMA
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP3585786C0 (en) COMPOUNDS FOR TREATING GLYCOGEN STORAGE DISEASES
EP3541379A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTONIA
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
EP3344650A4 (en) AAV-EPO FOR THE TREATMENT OF PETS
EP3373922A4 (en) COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA